HIPAA compliance you operate and can defend — not a binder you assemble.
Valentra Labs runs HIPAA Privacy and Security Rule posture as a live program on Valentra Nexus — a current risk analysis, the §164.308/.310/.312 evidence trail, breach-notification readiness, and BAA management — so the CCO meets an OCR audit with an operating record, not a binder.
Design partners
Valentra Labs is shaping Valentra Nexus with a founding cohort of design
partners. Here is where that program stands today.
EnrollingDesign partners onboarding now
Updated
The mandate a CCO owns
A CCO has to defend HIPAA compliance to an OCR investigator on the worst day, using evidence assembled on the best one. A risk analysis that is current only at sign-off, safeguards documented but not operated, BAAs tracked in a spreadsheet, and a breach-notification plan no one has exercised leave the defense resting on paper that has already gone stale.
Valentra Labs operates the compliance program rather than documenting it. Valentra Nexus keeps the HIPAA risk analysis current, carries the administrative, physical, and technical safeguard evidence required under §164.308, §164.310, and §164.312, manages the BAA inventory, and keeps breach-notification readiness exercised — packaged as a board-ready Decision Packet the CCO can put in front of OCR as a defensible operating record.
What CCOs say in our discovery calls
Drawn from how CCOs describe the problem in their own words — anonymized to role and organization type.
When OCR asks for our current risk analysis, I cannot hand them last year's spreadsheet and hope. I need it current and defensible. — CCO, multi-site provider
Documenting a safeguard is not operating it. In an audit I have to show the evidence trail, not the policy that promised one. — CCO, regional health system
Our BAAs and our breach plan live in three places and no one runs the drill. I need one operating record I can stand behind. — CCO, multi-specialty group
What the CCO reports to the board
The program produces one artifact the CCO can stand behind: a board-ready Decision Packet carrying the situation, options, recommendation, evidence, and approval chain — generated by Valentra Nexus.
Decision Packet · v1.0
Q2 2026 — Crown-Jewel Risk Disposition
pkt_2026-04-17_a3f8e1·
Situation
Q2 program review covers the crown-jewel ePHI store and its supporting control envelope. 487 endpoints catalogued across three network segments; 12 unsanctioned SaaS surfaces detected by the shadow-IT scan. Continuous monitoring posture is operating; the residual question is risk acceptance for two compensating-control gaps surfaced this cycle.
Risk & Impact
14 critical findings scored against the revenue-at-risk model. Two compensating gaps (vendor-SOC-2 attestation lapse + patch-cycle #38 awaiting CAB sign-off) carry residual risk of $1.4M in unmitigated regulatory exposure if a HITRUST audit lands before remediation closes. Patient-data confidentiality remains the load-bearing impact dimension.
Options
Accept residual risk through Q3, with quarterly board re-review.
Accelerate remediation by re-prioritizing the patch cycle ahead of the planned Q3 platform migration (cost: 2 engineer-weeks).
Transfer risk via expanded cyber-insurance rider (cost: $48K/yr premium delta; coverage gap on ePHI exfiltration remains).
Recommendation
Pursue Option 2 — accelerate remediation. The 2 engineer-weeks of effort cost is recoverable in Q3; the residual exposure is asymmetric (regulatory floor of $1.4M vs. ~$120K labor delta). Document the patch-cycle re-prioritization as a logged decision with the program owner; close the SOC-2 attestation gap via vendor outreach in the same window. Insurance rider deferred to Q4 review.
Evidence
Twelve evidence artifacts back the recommendation — asset inventory, control mapping, vendor SOC-2 status, residual-risk model, patch-cycle telemetry, and the prior packet's audit trail. One control attestation is overridden with a documented compensating-control narrative; two vendor attestations are pending the Q2 refresh window.
Overridden per compensating-control narrative — see attached
Penetration test report — Q1 follow-up
#a5b6c7d8
stale
—
Prior packet audit trail — pkt_2026-01-09_b8c4e2
#b6c7d8e9
verified
—
Approval Chain
CIO and CISO have signed. The CCO signature is pending receipt of the vendor-SOC-2 refresh; the program owner has logged the override and the compensating-control narrative.
Chief Information OfficerM. AlvarezSigned 2026-04-17T14:08:11Z
Chief Information Security OfficerJ. ParkSigned 2026-04-17T14:18:42Z
The program maps each operating stage — asset, risk, control, evidence, work, decision —
to the frameworks healthcare cybersecurity teams report against. Valentra Nexus carries
the full framework-alignment grid; see how the stages line up on the platform page.
Valentra Labs gives the CCO HIPAA compliance it operates and can defend: it keeps the risk analysis current, carries the §164.308/.310/.312 evidence trail, manages BAAs, and keeps breach-notification readiness exercised on Valentra Nexus — a board-ready operating record to put in front of OCR.